While overexpression of GIT2 has been described in the literature in breast and lung carcinomas [15, 16], this fusion with BRAF is novel in tumorigenesis and has not been described in any other type of tumor, hence it is difficult to predict the effect that the deletion will have on the GIT2 gene. Here, GIT2 is linked to neoplasm.